Sort
23,748 grants matching “melanoma”
Malignant Melanoma: Regulation by AP-2 and PAR-2
$264,250University Of Texas Md Anderson Can Ctr · R01 · FY2005 · CA
Utah Population Database (UPDB)
$264,222Ken R Smith · University Of Utah · P30 · FY2016 · CA
MELANOMA CELL SURFACE PROTEOGLYCANS IN METASTASIS
$264,199University Of Minnesota Twin Cities · R01 · FY2000 · CA
MOLECULAR PREDICTIVE TESTING IN OCULAR MELANOMA
$264,191James W Harbour · Washington University · R01 · FY2012 · CA
Use of Adjuvants to Improve Skin Genetic Immunizations
$264,149Adriana T Larregina · University Of Pittsburgh At Pittsburgh · R01 · FY2006 · CA
Transduction of T cells to improve migration to tumor
$264,095Patrick Hwu · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · CA
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors
$264,066James F Kronauge · Cytosite Biopharma, Inc. · R44 · FY2018 · CA
The DGCR8-mediated UV response pathway
$264,000Toshiyasu Taniguchi · Fred Hutchinson Cancer Research Center · R21 · FY2016 · ES
Polarization of Dendritic Cells by CD8 T cells
$263,996University Of Pittsburgh At Pittsburgh · R01 · FY2004 · CA
Protein Kinase Pathways in Cytokine-Signaling
$263,959Northwestern University · R01 · FY2005 · CA
SOUTHWEST ONCOLOGY GROUP
$263,942University Of Texas Hlth Sci Ctr San Ant · U10 · FY2002 · CA
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
$263,940Richard G Vile · Mayo Clinic Rochester · R01 · FY2017 · CA
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
$263,940Richard G Vile · Mayo Clinic Rochester · R01 · FY2015 · CA
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
$263,940Richard G Vile · Mayo Clinic Rochester · R01 · FY2014 · CA
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
$263,940Richard G Vile · Mayo Clinic Rochester · R01 · FY2016 · CA
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc
$263,862Juan Fernando Vera · Baylor College Of Medicine · P50 · FY2014 · CA
Targeting ROS enzymes in myeloid-derived suppressor cell to enhance immunotherapy
$263,733Tracy W Liu · West Virginia University · P20 · FY2022 · GM
Melanoma Cell Surface Proteoglycans in Metastasis
$263,718James B. McCarthy · University Of Minnesota · R01 · FY2006 · CA
A Phase I Proof-of-Concept Study of CBL0137 Combined with Ipilimumab and Nivolumab Therapy in Locally Advanced or Metastatic Melanoma
$263,670Igor Astsaturov · Research Inst Of Fox Chase Can Ctr · R21 · FY2023 · CA
The Role of EphA2 in UV-mediated Apoptosis
$263,625Hensin Tsao · Massachusetts General Hospital · R21 · FY2008 · ES
Therapy of Melanoma with Antigen Specific T Cell Clones
$263,623Fred Hutchinson Cancer Research Center · R21 · FY2002 · CA
Activation of pDCs in Murine Tumor Models
$263,575Willem W Overwijk · University Of Tx Md Anderson Can Ctr · P01 · FY2011 · CA
TC-Labeled Cyclic RGDfK Tetramers for Breast Cancer Imaging
$263,567Shuang Liu · Purdue University · R01 · FY2010 · CA
TC-Labeled Cyclic RGDfK Tetramers for Breast Cancer Imaging
$263,562Shuang Liu · Purdue University · R01 · FY2009 · CA
TC-Labeled Cyclic RGDfK Tetramers for Breast Cancer Imaging
$263,559Shuang Liu · Purdue University · R01 · FY2008 · CA